[Retracted] Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer

Table 2

Short-term efficacy evaluation.

Time point	CR	PR	SD	PD	ORR	DCR
1 month	0 (0)	2 (6.25)	6 (18.75)	24 (75.00)	2 (6.25)	8 (25.00)
3 months	0 (0)	4 (12.50)	8 (25.00)	20 (62.50)	4 (12.5)	12 (37.50)

Note: CR: complete remission; PR: partial remission; SD: stable disease; PD: progressive disease; ORR: overall response rate.